These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7490152)

  • 1. Contrasting effect of antihypertensive treatment on the renal response to L-arginine.
    Mimran A; Ribstein J; DuCailar G
    Hypertension; 1995 Dec; 26(6 Pt 1):937-41. PubMed ID: 7490152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension.
    Higashi Y; Oshima T; Sasaki S; Nakano Y; Kambe M; Matsuura H; Kajiyama G
    Hypertension; 1998 Jul; 32(1):16-24. PubMed ID: 9674632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study.
    Higashi Y; Sasaki S; Nakagawa K; Ueda T; Yoshimizu A; Kurisu S; Matsuura H; Kajiyama G; Oshima T
    J Am Coll Cardiol; 2000 Feb; 35(2):284-91. PubMed ID: 10676671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin-1-induced vasopressor responses in essential hypertension.
    Kaasjager KA; Koomans HA; Rabelink TJ
    Hypertension; 1997 Jul; 30(1 Pt 1):15-21. PubMed ID: 9231815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade.
    Himmelmann A; Hansson L; Hansson BG; Hedstrand H; Skogström K; Ohrvik J; Furängen A
    Am J Hypertens; 1996 Sep; 9(9):850-3. PubMed ID: 8879340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephroprotection by antihypertensive agents.
    Schmieder RE
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S55-64. PubMed ID: 7898095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy.
    Dieguez-Lucena JL; Aranda-Lara P; Ruiz-Galdón M; García-Villanova J; Morell-Ocaña M; Reyes-Engel A
    Hypertension; 1996 Jul; 28(1):98-103. PubMed ID: 8675271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
    Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
    Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kidney and antihypertensive therapy.
    Hollenberg NK
    Am J Cardiol; 1987 Jan; 59(2):76A-79A. PubMed ID: 2880492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent effects of ACE-inhibition and calcium channel blockade on NO-activity in systemic and renal circulation in essential hypertension.
    Dijkhorst-Oei LT; Beutler JJ; Stroes ES; Koomans HA; Rabelink TJ
    Cardiovasc Res; 1998 Nov; 40(2):402-9. PubMed ID: 9893735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trandolapril, but not verapamil nor their association, restores the physiological renal hemodynamic response to adrenergic activation in essential hypertension.
    Lambertucci L; Di Serio C; Castellani S; Torrini M; Lotti E; Cristofari C; Masotti G; Marchionni N; Ungar A
    Transl Res; 2011 Jun; 157(6):348-56. PubMed ID: 21575919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal consequences of antihypertensive therapy.
    Eknoyan G; Suki WN
    Semin Nephrol; 1991 Mar; 11(2):129-37. PubMed ID: 1674622
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of antihypertensive therapy on renal function.
    Rappelli A; Baldinelli A; Zingaretti O; Espinosa E; Salvi S; Fulgheri PD
    J Hypertens Suppl; 1991 Dec; 9(3):S37-40. PubMed ID: 1686783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kidney and strategies for the treatment of hypertension.
    Hollenberg NK
    Am J Med; 1984 Oct; 77(4A):60-3. PubMed ID: 6207726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of antihypertensive drug therapy on arterial compliance.
    Resnick LM; Lester MH
    Am J Hypertens; 2002 Dec; 15(12):1096-100. PubMed ID: 12460707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive therapy and mobilization of renal functional reserve.
    Burnier M; Biollaz J; Steinhauslin F; Brouard R; Waeber B; Brunner HR
    Clin Invest Med; 1991 Dec; 14(6):581-9. PubMed ID: 1686579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rational approach to hypertension treatment in the older patient.
    Flack JM; Woolley A; Esunge P; Grimm RH
    Geriatrics; 1992 Nov; 47(11):24-8, 33-8. PubMed ID: 1358761
    [No Abstract]   [Full Text] [Related]  

  • 19. Vasodilators, antihypertensive therapy and the kidney.
    Hollenberg NK
    Am J Cardiol; 1987 Dec; 60(17):57I-60I. PubMed ID: 3687806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive medications.
    Slagle MA
    South Med J; 2001 Nov; 94(11):1071-3. PubMed ID: 11780676
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.